BMC Pregnancy and Childbirth (Jan 2024)

Neonatal outcomes and follow-up of children born to women with pregnancy-associated cancer: a prospective observational study

  • Michele Antonio Capozza,
  • Alberto Romano,
  • Stefano Mastrangelo,
  • Giorgio Attinà,
  • Palma Maurizi,
  • Simonetta Costa,
  • Giovanni Vento,
  • Giovanni Scambia,
  • Antonio Ruggiero

DOI
https://doi.org/10.1186/s12884-023-06182-4
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background During the last decade, there has been a growing number of cases of children born from pregnancy-associated cancer (PAC), however there are currently insufficient data on the follow up to be observed in this category of newborns. Objective of the study was to evaluate the neonatal outcomes of infants born to mother with PAC, the potential adverse effect of chemotherapy during pregnancy and the risk of metastasis to the fetus. Methods Maternal clinical data and neonatal outcomes of child born to mothers diagnosed with PAC were collected; infants were divided into those were and were not exposed to chemotherapy during fetal life and their outcomes were compered. Results A total of 37 newborn infants from 36 women with PAC were analyzed. Preterm delivery occurred in 83.8% of the cases. No significant differences in neonatal outcomes were found between infants who were and were not exposed to chemotherapy during pregnancy. The median follow-up period was 12 months. Conclusions PAC treatment during the second or third trimester does not seem to be dangerous for the fetus, however infants born from PAC must be carefully evaluated for to rule out the consequences of chemotherapy and exclude the presence of metastasis. Long-term follow-up, especially in children exposed to chemotherapy, should be encouraged to obtain relevant data on long-term toxicity.

Keywords